New combo pill aims to crush stubborn high cholesterol
NCT ID NCT07442630
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a fixed-dose combination pill containing Pitavastatin and Ezetimibe against Pitavastatin alone in 88 people with high cholesterol and high triglycerides. Participants take the pill daily for 52 weeks. The main goal is to see how much LDL ('bad') cholesterol drops after 8 weeks, with longer-term effects on HDL and triglycerides also measured.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pitavastatin and Ezetimibe combination pill
What this could lead to
If successful, this could provide a more effective long-term option for managing high cholesterol and reducing heart disease risk.
What could go wrong
This is a Phase 4 study, so the drugs are already approved; the main uncertainties are about long-term safety and whether the combination works better than Pitavastatin alone. Side effects like muscle pain or liver issues are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Catholic University of Korea, Yeouido St. Mary's Hospital
Seoul, South Korea